Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisFRA:EX9 +3.50%90 Receivables Turnover is 1.93 as of Jun. 2026. GuruFocus rates FRA:EX9 with a GF Score™ of 90/100 and a GF Value™ of €40.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 847 Biotechnology companies, Exelixis ranks better than 69.3% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Exelixis's Revenue for the
three
months ended in Jun. 2026 was €546 Mil. Exelixis's average Accounts Receivable for the
three
months ended in Jun. 2026 was €282 Mil.
Hence, Exelixis's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.93.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Exelixis Receivables Turnover Related Terms
Exelixis Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Exelixis's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EX9 vs MDGL, AXSM, ARWR: Receivables Turnover Comparison
For the Biotechnology subindustry, Exelixis's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Exelixis's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (FRA:EX9) has a Receivables Turnover of 1.93 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Exelixis and its competitors. According to the industry distribution chart, Exelixis ranks #260 out of 847 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Exelixis' Receivables Turnover too high?
Exelixis' current Receivables Turnover is 1.93. The Biotechnology industry median Receivables Turnover is 5.27. Exelixis' value of 1.93 is 63.4% below this industry median. Based on the distribution chart, Exelixis ranks #260 out of 847 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Receivables Turnover compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #260 out of 847 companies for Receivables Turnover. This puts Exelixis in the upper half of its industry. The industry median Receivables Turnover is 5.27. Exelixis' value of 1.93 is 63.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exelixis's current Receivables Turnover of 1.93 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Exelixis and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exelixis's current Receivables Turnover is 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current Receivables Turnover is 1.93 and 63.4% below the Biotechnology industry median of 5.27. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current Receivables Turnover is 1.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (FRA:EX9) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for FRA:EX9:
Receivables Turnover: 1.93
GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
Industry Position: 63.4% below the Biotechnology median (#260 of 847)
No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score
Get the complete analysis for FRA:EX9
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EX9 has been successfully added to your 
